Niklas Mattsson-Carlgren
Malmoe, M, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 200 publications
Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease.
Journal: JAMA neurology
Published: May 26, 2026
Generating synthetic tau-PET scans in Alzheimer's disease from MRI, blood biomarkers and demographics with deep learning.
Journal: medRxiv : the preprint server for health sciences
Published: May 18, 2026
The Role of Clinical, Plasma, and Imaging Biomarkers in Assessing Future Dementia Risk in Individuals With Subjective Cognitive Decline.
Journal: Neurology
Published: May 14, 2026
Stable episodic memory and high education do not influence the rate of Alzheimer's disease pathology as measured by plasma p-tau217.
Journal: bioRxiv : the preprint server for biology
Published: May 04, 2026
Multicenter validation of plasma p-tau217/ amyloid beta 1-42 ratio in symptomatic Alzheimer's disease.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: March 19, 2026
Plasma and CSF proteomic signatures related to Alzheimer's, α-synuclein, or vascular pathologies and clinical decline.
Journal: medRxiv : the preprint server for health sciences
Published: February 12, 2026
Clinical staging in Swedish primary care using the Amsterdam Instrumental Activities of Daily Living Questionnaire.
Journal: Alzheimer's & dementia (Amsterdam, Netherlands)
Published: January 29, 2026
Tau-PET and CSF MTBR-tau243 comparisons validate increased tau aggregation in females.
Journal: European journal of nuclear medicine and molecular imaging
Published: January 18, 2026
Eligibility for amyloid targeting therapies among primary care patients with cognitive symptoms.
Journal: Alzheimer's research & therapy
Published: December 22, 2025
Last Updated: 09/26/2026